Antibody neutralization capacity after coronavirus disease 2019 vaccination in people with HIV in Canada

Costiniuk, Cecilia T.; Singer, Joel; Lee, Terry; Galipeau, Yannick; McCluskie, Pauline S.; Arnold, Corey; Langlois, Marc-André; Needham, Judy; Jenabian, Mohammad-Ali; Burchell, Ann N.; Samji, Hasina; Chambers, Catharine; Walmsley, Sharon; Ostrowski, Mario; Kovacs, Colin; Tan, Darrell H. S.; Harris, Marianne; Hull, Mark; Brumme, Zabrina L.; Lapointe, Hope R.; Vulesevic, Branka; Brockman, Mark A.; Margolese, Shari; Mandarino, Enrico; Samarani, Suzanne; Lebouché, Bertrand; Angel, Jonathan B.; Routy, Jean-Pierre; Cooper, Curtis L.; Anis, Aslam H.; COVAXHIV Study Group

doi:https://open-science.canada.ca/handle/123456789/2730

Antibody neutralization capacity after coronavirus disease 2019 vaccination in people with HIV in Canada

Simple item page

Full item details

dc.contributor.author: Costiniuk, Cecilia T.; Singer, Joel; Lee, Terry; Galipeau, Yannick; McCluskie, Pauline S.; Arnold, Corey; Langlois, Marc-André; Needham, Judy; Jenabian, Mohammad-Ali; Burchell, Ann N.; Samji, Hasina; Chambers, Catharine; Walmsley, Sharon; Ostrowski, Mario; Kovacs, Colin; Tan, Darrell H. S.; Harris, Marianne; Hull, Mark; Brumme, Zabrina L.; Lapointe, Hope R.; Vulesevic, Branka; Brockman, Mark A.; Margolese, Shari; Mandarino, Enrico; Samarani, Suzanne; Lebouché, Bertrand; Angel, Jonathan B.; Routy, Jean-Pierre; Cooper, Curtis L.; Anis, Aslam H.; COVAXHIV Study Group
dc.date.accessioned: 2024-07-26T20:22:08Z
dc.date.available: 2024-07-26T20:22:08Z
dc.date.issued: 2023-10-01
dc.description.abstract - en: Objectives: Many vaccines require higher/additional doses or adjuvants to provide adequate protection for people with HIV (PWH). Here, we compare coronavirus disease 2019 (COVID-19) vaccine-induced antibody neutralization capacity in PWH vs. HIV-negative individuals following two vaccine doses. Design: In Canadian prospective observational cohorts, including a multicentre study of PWH receiving at least two COVID-19 vaccinations (mRNA or ChAdOx1-S), and a parallel study of HIV-negative controls (Stop the Spread Ottawa Cohort), we measured vaccine-induced neutralization capacity 3 months post dose 2 (±1 month). Methods: COVID-19 neutralization efficiency was measured by calculating the half maximal inhibitory dilution (ID50) using a high-throughput protein-based neutralization assay for Ancestral (Wuhan), Delta and Omicron (BA.1) spike variants. Univariable and multivariable quantile regression were used to compare COVID-19-specific antibody neutralization capacity by HIV status. Results: Neutralization assays were performed on 256 PWH and 256 controls based on specimen availability at the timepoint of interest, having received two vaccines and known date of vaccination. There was a significant interaction between HIV status and previous COVID-19 infection status in median ID50. There were no differences in median ID50 for HIV+ vs. HIV-negative persons without past COVID-19 infection. For participants with past COVID-19 infection, median ICD50 was significantly higher in controls than in PWH for ancestral SARS-CoV-2 and Omicron variants, with a trend for the Delta variant in the same direction. Conclusion: Vaccine-induced SARS-CoV-2 neutralization capacity was similar between PWH vs. HIV-negative persons without past COVID-19 infection, demonstrating favourable humoral-mediated immunogenicity. Both HIV+ and HIV-negative persons demonstrated hybrid immunity.
dc.description.sponsorship - en: This project was supported by funding from the Public Health Agency of Canada, through the Vaccine Surveillance Reference group and the COVID-19 Immunity Task Force (grant number: 2122-HQ-000075) and the CTN (grant number: N/A). Production of COVID-19 reagents was financially supported by NRC's Pandemic Response Challenge Program.
dc.identifier.doi: https://doi.org/10.1097/qad.0000000000003680
dc.identifier.issn: 0269-9370
dc.identifier.pubmedID: 37534695
dc.identifier.uri: https://open-science.canada.ca/handle/123456789/2730
dc.language.iso: en
dc.publisher: Wolters Kluwer Health, Inc.
dc.rights - en: Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
dc.rights - fr: Creative Commons Attribution - Pas d'utilisation commerciale - Pas de modification 4.0 International (CC BY-NC-ND 4.0)
dc.rights.openaccesslevel - en: Gold
dc.rights.openaccesslevel - fr: Or
dc.rights.uri - en: https://creativecommons.org/licenses/by-nc-nd/4.0/
dc.rights.uri - fr: https://creativecommons.org/licenses/by-nc-nd/4.0/deed.fr
dc.subject - en: Health; Coronavirus diseases
dc.subject - fr: Santé; Maladie à coronavirus
dc.subject.en - en: Health; Coronavirus diseases
dc.subject.fr - fr: Santé; Maladie à coronavirus
dc.title - en: Antibody neutralization capacity after coronavirus disease 2019 vaccination in people with HIV in Canada
dc.type - en: Article
dc.type - fr: Article
local.article.journalissue: 12
local.article.journaltitle: AIDS
local.article.journalvolume: 37
local.pagination: F25-F35
local.peerreview - en: Yes
local.peerreview - fr: Oui

Download(s)

Original bundle

Now showing 1 - 1 of 1

Name: costiniuk-antibody-neutralization-capacity-after-coronavirus.pdf

Size: 582.04 KB

Format: PDF

Download file

Collection(s)

Communicable diseases